Analysis of the transforming growth factor β1 gene L509 C/T polymorphism in patients with advanced-stage endometriosis

Objective: To investigate whether the transforming growth factor beta (TGF-beta) gene -509 C/T polymorphism is associated with susceptibility to advanced-stage endometriosis. Design: Case-control study. Setting: University department of obstetrics and gynecology. Patient(s): Women with advanced-stage endometriosis (n = 485) and without endometriosis (n 352). Intervention(s): Genotyping by real-time polymerase chain reaction using a Taqman assay. Main Outcome Measure(s): Genotype distribution and allele frequency of the -509 C/T polymorphism in the TGF-beta 1 gene. Result(s): The genotype distribution of the TGF-beta 1 gene -509 C/T polymorphism in the endometriosis group was not different from that of the control group (CC/CT/TT rates were 29.3%/48.2%/22.5% and 27.3%/50.3%/22.4% for the endometriosis and control groups, respectively). Further subgroup analyses according to the stage of endometriosis or bilaterality of ovarian endometrioma also revealed no significant differences in the genotype distribution between each of the subgroups and the control group. Conclusion(s): These results suggest that the TGF-beta 1 -509 C/T polymorphism may not be associated with an increased risk for advanced-stage endometriosis. (Fertil Steril (R) 2010;93:2121-4. (C)2010 by American Society for Reproductive Medicine.)Supported by a grant from the Korea Health 21 R&D Project, Ministry of Health and Welfare, Republic of Korea (01-PJ10-PG6–01GN13–0002).Bertolino P, 2005, CHEST, V128, p585SKim SH, 2005, HUM REPROD, V20, P2904, DOI 10.1093/humrep/dei146Shin AS, 2005, CANCER EPIDEM BIOMAR, V14, P1567Hsieh YY, 2005, BIOCHEM GENET, V43, P203, DOI 10.1007/s10528-005-5211-xElliott RL, 2005, J CLIN ONCOL, V23, P2078, DOI 10.1200/JCO.2005.02.047Salanti G, 2005, GENET MED, V7, P13Nap AW, 2004, J CLIN ENDOCR METAB, V89, P1089, DOI 10.1210/jc.2003-031406Bischoff F, 2004, ANN NY ACAD SCI, V1034, P284, DOI 10.1196/annals.1335.030Goumans MJ, 2003, TRENDS CARDIOVAS MED, V13, P301Shi YG, 2003, CELL, V113, P685MISSMER SA, 2003, OBSTET GYN CLIN N AM, V30, P1Hadfield RM, 2001, MOL HUM REPROD, V7, P1073Zondervan KT, 2001, CURR OPIN OBSTET GYN, V13, P309Campbell I, 2001, RAPID PROTOTYPING J, V7, P5Grainger DJ, 1999, HUM MOL GENET, V8, P93Taylor RN, 1997, ANN NY ACAD SCI, V828, P194*AM SOC REPR MED, 1996, FERTIL STERIL, V1997, P817MARSHBURN PB, 1994, AM J OBSTET GYNECOL, V170, P1152HAMMOND MG, 1993, AM J OBSTET GYNECOL, V168, P1131OOSTERLYNCK DJ, 1992, FERTIL STERIL, V58, P290KANZAKI H, 1992, AM J OBSTET GYNECOL, V167, P257TANAKA E, 1992, GYNECOL OBSTET INVES, V34, P27ROOK AH, 1986, J IMMUNOL, V136, P3916FUJII D, 1986, SOMAT CELL MOLEC GEN, V12, P281